Battelle Awarded $59m Contract

Battelle infectious diseases and medical countermeasure work awarded with new $59 million contract by the U.S. Army Joint Program Executive Office for Chemical and Biological Defense, which funds research to create vaccines and therapeutics for biological and chemical threats

Battelle was chosen to protect warfighters and the general public against dangerous infectious disease and chemical threats under a new contract award from the DoD. It’s part of an OASIS contract mechanism that is worth up to $59 million, including all options, over the next five years. Work covered by this latest contract includes development of vaccines for potentially weaponized viruses such as plague, botulinum, equine encephalitis, and filovirus, and medical countermeasures against multiple nerve agents and poisonous toxins used in chemical warfare.

“We’re proud of the work we do at Battelle to protect people from threats like the Ebola and Zika viruses or ricin,” said Julie Swick, general manager for Battelle’s Life Sciences Research group. “Our dedicated employees come into work every day knowing they are contributing solutions to important, worldwide problems.” Battelle has conducted research designed to protect the military from these threats for decades. Frequently, the vaccines and therapeutics developed and tested on these programs then make their way into the civilian protection programme.

Tags: Threat, Chemical, Military, Protection, Contract, Warfare

Our Current Sponsors

  • Flir
  • BioFire Defense
  • Federal Resources
  • Cristanini
  • Airboss
  • Flir
  • Tex Shield
  • Argon
  • 908 Devices
  • Avon
  • Flir
  • Battelle
  • Bw Tek
  • CQC
  • Decon Seven Systems
  • Flir
  • DQE
  • Dxterity
  • First Line Technology
  • Futurtech
  • Flir
  • Metrohm Raman
  • NBC sys
  • Proengin
  • Qinetiq
  • Flir
  • Tex Shield
  • Wl Gore
  • ADS, Inc.
  • Rigaku Analytical Devices
  • Flir
  • Paul Boye Technologies
  • Observis
  • Zeteo Tech
  • Bertin Instruments
  • ECOTEST
  • Tex Shield